SEROTONERGIC MECHANISMS IN THE DEVELOPMENT OF LEVODOPA-INDUCED MOTOR AND NON-MOTOR DISORDERS IN PARKINSON’S DISEASE
Keywords:
Parkinson’s disease, serotonin, dopamine, blood plasma, non-motor symptoms, cognitive impairmentAbstract
150 patients were examined with Parkinson’s disease. All participants underwent a comprehensive clinical, neurological, and neuropsychological evaluation, including measurement of serotonin and dopamine levels in blood plasma. Most patients showed a reduced level of serotonin, while dopamine levels remained within normal limits or were elevated. Lower serotonin levels were associated with more pronounced non-motor symptoms, particularly depression, anxiety, and cognitive impairment.
References
Рахимбаева Г. С., Насруллаев Б. Б., Юнусова М. Р. Сравнительная характеристика немоторных проявлений болезни Паркинсона и сосудистого паркинсонизма // Журнал Неврологии и Нейрохирургических исследований. – 2021. – Спец. выпуск. – С. 88–90.
Politis M., Loane C. Serotonergic dysfunction in Parkinson’s disease and its relevance to disability // ScientificWorldJournal. – 2011. – Vol. 11. – P. 1726–1734.
Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats // Brain. – 2007. – Vol. 130. – P. 1819–1833.
Huot P., Fox S. H., Brotchie J. M. The serotonergic system in Parkinson’s disease // Progress in Neurobiology. – 2011. – Vol. 95(2). – P. 163–212.
Politis M. Neuroimaging in Parkinson’s disease: Understanding the role of serotonin // Movement Disorders. – 2015. – Vol. 30(7). – P. 867–871.
Pavese N., Evans A. H., Tai Y. F., et al. Clinical correlates of levodopa-induced dyskinesias in Parkinson’s disease: a combined PET study // Brain. – 2006. – Vol. 129(3). – P. 661–668.
Aarsland D., Marsh L., Schrag A. Neuropsychiatric symptoms in Parkinson’s disease // Movement Disorders. – 2009. – Vol. 24(15). – P. 2175–2186.
Bédard M. A., Parent A., Saint-Hilaire M., Strazielle C. Serotonin and motor control in Parkinson’s disease: a review of the evidence // Revue Neurologique (Paris). – 2011. – Vol. 167(11). – P. 880–886.
Politis M., Loane C. Serotonergic dysfunction in Parkinson’s disease and its relevance to disability // ScientificWorldJournal. – 2011. – Vol. 11. – P. 1726–1734.
Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats // Brain. – 2007. – Vol. 130. – P. 1819–1833.
Huot P., Fox S. H., Brotchie J. M. The serotonergic system in Parkinson’s disease // Progress in Neurobiology. – 2011. – Vol. 95(2). – P. 163–212.
Politis M. Neuroimaging in Parkinson’s disease: Understanding the role of serotonin // Movement Disorders. – 2015. – Vol. 30(7). – P. 867–871.
Khaydarova D.K., Mansurova N.A. Analysis of Motor Complications in Parkinson’s Disease Phenotypes. Journal of Advances in Medicine and Medical Research. 25(5): 1-7, 2018;
Aarsland D., Marsh L., Schrag A. Neuropsychiatric symptoms in Parkinson’s disease // Movement Disorders. – 2009. – Vol. 24(15). – P. 2175–2186.
Bédard M. A., Parent A., Saint-Hilaire M., Strazielle C. Serotonin and motor control in Parkinson’s disease: a review of the evidence // Revue Neurologique (Paris). – 2011. – Vol. 167(11). – P. 880–886.
Rylander D., Parent M., O'Sullivan S. S., et al. Serotonergic neurons mediate dyskinesia side effects of Parkinson's medications // Journal of Clinical Investigation. – 2010. – Vol. 120(7). – P. 2347–2355.
Loane C., Politis M. Buspirone: A new player in the treatment of Parkinson’s disease dyskinesia? // Movement Disorders Clinical Practice. – 2012. – Vol. 29(1). – P. 17–23.
Pifl C., Rajput A., Reither H., Blesa J., Cavada C., Obeso J. A. Is Parkinson's disease a vesicular dopamine storage disorder? // Movement Disorders. – 2014. – Vol. 29(7). – P. 904–911.
